Anthony Nicholas

10 Patents

• US125827182026

  Integrin Targeting Ligands and Uses Thereof

  Arrowhead Pharmaceuticals, Inc.

  0 cites
• US124865022025

  Rnai Agents for Inhibiting Expression of Receptor for Advanced Glycation End-products, Compositions Thereof, and Methods of Use

  Arrowhead Pharmaceuticals, Inc.

  0 cites
• US123658972025

  Rnai Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use

  Arrowhead Pharmaceuticals, Inc.

  0 cites
• US122216102025

  Rnai Agents for Inhibiting Expression of HIF-2 Alpha ( EPAS1 ), Compositions Thereof, and Methods of Use

  Arrowhead Pharmaceuticals, Inc.

  0 cites
• US121730862024

  Alpha-v Beta-6 Integrin Ligands and Uses Thereof

  Arrowhead Pharmaceuticals, Inc.

  0 cites
• US120547182024

  Rnai Agents for Inhibiting Expression of PNPLA3, Pharmaceutical Compositions Thereof, and Methods of Use

  Arrowhead Pharmaceuticals, Inc.

  0 cites
• US119129972024

  Rnai Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use

  Arrowhead Pharmaceuticals, Inc.

  0 cites
• US118459372023

  Rnai Agents for Inhibiting Expression of DUX4, Compositions Thereof, and Methods of Use

  Arrowhead Pharmaceuticals, Inc.

  0 cites
• US116293492023

  Rnai Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use

  ARROWHEAD PHARMACEUTICALS, Inc.

  0 cites
• US115491122023

  Rnai Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use

  ARROWHEAD PHARMACEUTICALS, Inc.

  0 cites